^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Glioma |
| Drug: | temozolomide (DNA synthesis inhibitor) + AZD9574 (PARP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1
Published date:
11/15/2023
Excerpt:
In an O6-methylguanine-DNA methyltransferase (MGMT)-methylated orthotopic glioma model, AZD9574 in combination with TMZ was superior in extending the survival of tumor-bearing mice compared to TMZ alone.
DOI:
10.1158/1078-0432.CCR-23-2094
